Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

- Secures $3.2m in PIPE Financing -
- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -

BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. (Peak Bio), creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. The combined entity will continue the two companies’ significant progress in the development of Antibody Drug Conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including Geographic Atrophy (GA).

Read more at globenewswire.com